A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): case report and coagulation studies.

A Hitherto Undescribed Plasma Factor Acting at the Contact Phase of Blood Coagulation ( Flaujeac Factor )

This paper reports an asymptomatic coagulation defect responsible for an abnormality at the contact phase of blood coagulation in vitro, distinct from Hageman factor and Fletcher factor deficiencies. Coagulation studies in a 50-yr-old French woman without bleeding tendency revealed the following results: whole-blood clotting time in glass tubes and activated partial thromboplastin time with kao...

Blood Coagulation Induced by Iranian Saw-Scaled Viper (Echis Carinatus) Venom: Identification, Purification and Characterization of a Prothrombin Activator

  Objective(s): Echis carinatus is one of the venomous snakes in Iran. The venom of Iranian Echis carinatus is a rich source of protein with various factors affecting the plasma protein and blood coagulation factor. Some of these proteins exhibit types of enzymatic activities. However, other items are proteins with no enzymatic activity.   Materials and Methods: In order to study the mechanism ...

In Vitro and in Vivo studies of the Effects of Cold Argon Plasma on Decreasing the Coagulation Time

Introduction Cold plasma is a self-sterilized, painless, and non-contact method in surgeries. These properties allow it to be applied to the living tissues and heat-sensitive parts. The aim of this study was to design a new cold plasma producer device and evaluate the effects of cold argon plasma on decreasing the coagulation time of blood drop in vitro and that of the injured liver blood in vi...

Expression of Recombinant Coagulation Factor IX in Human Amniotic Membrane-derived Mesenchymal Stem Cells: A New Strategy to Gene Therapy of Hemophilia B

Background: Hemophilia B is an X-linked hereditary disorder of blood coagulation system which is caused by factor IX (FIX) deficiency. Factor IX is a plasma glycoprotein that participates in the coagulation process leading to the generation of fibrin. Replacement of factor IX with plasma-derived or recombinant factor IX is the conventional treatment for hemophilia B to raise the factor IX le...

Plasma thromboplastin component (PTC), a hitherto unrecognized blood coagulation factor; case report of PTC deficiency.